Literature DB >> 30976808

Identification of Candidates for Longer Lung Cancer Screening Intervals Following a Negative Low-Dose Computed Tomography Result.

Hilary A Robbins, Christine D Berg, Li C Cheung, Anil K Chaturvedi, Hormuzd A Katki.   

Abstract

Lengthening the annual low-dose computed tomography (CT) screening interval for individuals at lowest risk of lung cancer could reduce harms and improve efficiency. We analyzed 23 328 participants in the National Lung Screening Trial who had a negative CT screen (no ≥4-mm nodules) to develop an individualized model for lung cancer risk after a negative CT. The Lung Cancer Risk Assessment Tool + CT (LCRAT+CT) updates "prescreening risk" (calculated using traditional risk factors) with selected CT features. At the next annual screen following a negative CT, risk of cancer detection was reduced among the 70% of participants with neither CT-detected emphysema nor consolidation (median risk = 0.2%, interquartile range [IQR] = 0.1%-0.3%). However, risk increased for the 30% with CT emphysema (median risk = 0.5%, IQR = 0.3%-0.8%) and the 0.6% with consolidation (median = 1.6%, IQR = 1.0%-2.5%). As one example, a threshold of next-screen risk lower than 0.3% would lengthen the interval for 57.8% of screen-negatives, thus averting 49.8% of next-screen false-positives among screen-negatives but delaying diagnosis for 23.9% of cancers. Our results support that many, but not all, screen-negatives might reasonably lengthen their CT screening interval. © World Health Organization, 2019. All rights reserved. The World Health Organization has granted the Publisher permission for the reproduction of this article.

Entities:  

Mesh:

Year:  2019        PMID: 30976808      PMCID: PMC6748798          DOI: 10.1093/jnci/djz041

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  26 in total

1.  Raising the bar for the U.S. Preventive Services Task Force.

Authors:  Peter B Bach
Journal:  Ann Intern Med       Date:  2014-03-04       Impact factor: 25.391

2.  Probability of cancer in pulmonary nodules detected on first screening CT.

Authors:  Annette McWilliams; Martin C Tammemagi; John R Mayo; Heidi Roberts; Geoffrey Liu; Kam Soghrati; Kazuhiro Yasufuku; Simon Martel; Francis Laberge; Michel Gingras; Sukhinder Atkar-Khattra; Christine D Berg; Ken Evans; Richard Finley; John Yee; John English; Paola Nasute; John Goffin; Serge Puksa; Lori Stewart; Scott Tsai; Michael R Johnston; Daria Manos; Garth Nicholas; Glenwood D Goss; Jean M Seely; Kayvan Amjadi; Alain Tremblay; Paul Burrowes; Paul MacEachern; Rick Bhatia; Ming-Sound Tsao; Stephen Lam
Journal:  N Engl J Med       Date:  2013-09-05       Impact factor: 91.245

Review 3.  Benefits and harms of CT screening for lung cancer: a systematic review.

Authors:  Peter B Bach; Joshua N Mirkin; Thomas K Oliver; Christopher G Azzoli; Donald A Berry; Otis W Brawley; Tim Byers; Graham A Colditz; Michael K Gould; James R Jett; Anita L Sabichi; Rebecca Smith-Bindman; Douglas E Wood; Amir Qaseem; Frank C Detterbeck
Journal:  JAMA       Date:  2012-06-13       Impact factor: 56.272

4.  Reduced lung-cancer mortality with low-dose computed tomographic screening.

Authors:  Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D Clapp; Richard M Fagerstrom; Ilana F Gareen; Constantine Gatsonis; Pamela M Marcus; JoRean D Sicks
Journal:  N Engl J Med       Date:  2011-06-29       Impact factor: 91.245

5.  Overdiagnosis in lung cancer screening: why modelling is essential.

Authors:  Kevin Ten Haaf; Harry J de Koning
Journal:  J Epidemiol Community Health       Date:  2015-06-12       Impact factor: 3.710

6.  Low-dose computed tomography for lung cancer screening: comparison of performance between annual and biennial screen.

Authors:  Nicola Sverzellati; M Silva; G Calareso; C Galeone; A Marchianò; S Sestini; G Sozzi; U Pastorino
Journal:  Eur Radiol       Date:  2016-02-11       Impact factor: 5.315

7.  Characteristics of lung cancers detected by computer tomography screening in the randomized NELSON trial.

Authors:  Nanda Horeweg; Carlijn M van der Aalst; Erik Thunnissen; Kristiaan Nackaerts; Carla Weenink; Harry J M Groen; Jan-Willem J Lammers; Joachim G Aerts; Ernst T Scholten; Joost van Rosmalen; Willem Mali; Matthijs Oudkerk; Harry J de Koning
Journal:  Am J Respir Crit Care Med       Date:  2013-04-15       Impact factor: 21.405

8.  Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening.

Authors:  Nanda Horeweg; Joost van Rosmalen; Marjolein A Heuvelmans; Carlijn M van der Aalst; Rozemarijn Vliegenthart; Ernst Th Scholten; Kevin ten Haaf; Kristiaan Nackaerts; Jan-Willem J Lammers; Carla Weenink; Harry J Groen; Peter van Ooijen; Pim A de Jong; Geertruida H de Bock; Willem Mali; Harry J de Koning; Matthijs Oudkerk
Journal:  Lancet Oncol       Date:  2014-10-01       Impact factor: 41.316

9.  Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2014-03-04       Impact factor: 25.391

10.  Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force.

Authors:  Harry J de Koning; Rafael Meza; Sylvia K Plevritis; Kevin ten Haaf; Vidit N Munshi; Jihyoun Jeon; Saadet Ayca Erdogan; Chung Yin Kong; Summer S Han; Joost van Rosmalen; Sung Eun Choi; Paul F Pinsky; Amy Berrington de Gonzalez; Christine D Berg; William C Black; Martin C Tammemägi; William D Hazelton; Eric J Feuer; Pamela M McMahon
Journal:  Ann Intern Med       Date:  2014-03-04       Impact factor: 25.391

View more
  18 in total

1.  Optimal lung cancer screening intervals following a negative low-dose computed tomography result.

Authors:  Monica E Reyes; Matthew B Schabath
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

2.  Lung cancer screening: tell me more about post-test risk.

Authors:  Mario Silva; Gianluca Milanese; Ugo Pastorino; Nicola Sverzellati
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

3.  Adherence to annual lung cancer screening with low-dose CT scan in a diverse population.

Authors:  Cherie P Erkmen; Farouk Dako; Ryan Moore; Chandra Dass; Mark G Weiner; Larry R Kaiser; Grace X Ma
Journal:  Cancer Causes Control       Date:  2021-01-04       Impact factor: 2.506

Review 4.  Lung Cancer Screening with Low-Dose CT: a Meta-Analysis.

Authors:  Richard M Hoffman; Rami P Atallah; Roger D Struble; Robert G Badgett
Journal:  J Gen Intern Med       Date:  2020-06-24       Impact factor: 5.128

5.  Ten-year results of the Multicentric Italian Lung Detection trial demonstrate the safety and efficacy of biennial lung cancer screening.

Authors:  U Pastorino; N Sverzellati; S Sestini; M Silva; F Sabia; M Boeri; A Cantarutti; G Sozzi; G Corrao; A Marchianò
Journal:  Eur J Cancer       Date:  2019-07-20       Impact factor: 9.162

6.  Evaluation of benefits and harms of adaptive screening schedules for lung cancer: A microsimulation study.

Authors:  Pianpian Cao; Jihyoun Jeon; Rafael Meza
Journal:  J Med Screen       Date:  2022-08-22       Impact factor: 1.687

7.  Multistate models for the natural history of cancer progression.

Authors:  Li C Cheung; Paul S Albert; Shrutikona Das; Richard J Cook
Journal:  Br J Cancer       Date:  2022-07-11       Impact factor: 9.075

8.  A risk-based framework for assessing real-time lung cancer screening eligibility that incorporates life expectancy and past screening findings.

Authors:  Iakovos Toumazis; Oguzhan Alagoz; Ann Leung; Sylvia K Plevritis
Journal:  Cancer       Date:  2021-08-12       Impact factor: 6.860

Review 9.  Integrated imaging and molecular analysis to decipher tumor microenvironment in the era of immunotherapy.

Authors:  Jia Wu; Aaron T Mayer; Ruijiang Li
Journal:  Semin Cancer Biol       Date:  2020-12-05       Impact factor: 17.012

Review 10.  Recommendations for Implementing Lung Cancer Screening with Low-Dose Computed Tomography in Europe.

Authors:  Giulia Veronesi; David R Baldwin; Claudia I Henschke; Simone Ghislandi; Sergio Iavicoli; Matthijs Oudkerk; Harry J De Koning; Joseph Shemesh; John K Field; Javier J Zulueta; Denis Horgan; Lucia Fiestas Navarrete; Maurizio Valentino Infante; Pierluigi Novellis; Rachael L Murray; Nir Peled; Cristiano Rampinelli; Gaetano Rocco; Witold Rzyman; Giorgio Vittorio Scagliotti; Martin C Tammemagi; Luca Bertolaccini; Natthaya Triphuridet; Rowena Yip; Alexia Rossi; Suresh Senan; Giuseppe Ferrante; Kate Brain; Carlijn van der Aalst; Lorenzo Bonomo; Dario Consonni; Jan P Van Meerbeeck; Patrick Maisonneuve; Silvia Novello; Anand Devaraj; Zaigham Saghir; Giuseppe Pelosi
Journal:  Cancers (Basel)       Date:  2020-06-24       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.